Tyra Biosciences, Inc.
TYRA evidence brief
What we can confirm
- BioSniper Score:
- 7.7 / 10
- Market Cap:
- $1.59B
- Lead Asset:
- dabogratinib (Phase 2)
What it means
What to watch
Prepared research question
What matters most for TYRA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TYRA
Tyra Biosciences (TYRA) is a clinical-stage biotechnology company developing next-generation precision FGFR inhibitors, with a lead candidate dabogratinib showing a 57% complete response rate in a Phase 2 trial for intermediate-risk non-muscle invasive bladder cancer as of September 2026.
Key risk: High net loss
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 8 clinical trials for Tyra Biosciences, Inc..
Tyra Biosciences (TYRA) is a clinical-stage biotechnology company developing next-generation precision FGFR inhibitors, with a lead candidate dabogratinib showing a 57% complete response rate in a Phase 2 trial for intermediate-risk non-muscle invasive bladder cancer as of September 2026.
- Cash & equivalents of $73.8M as of 2026-06-30 [sec].
- Net income of -$45.6M as of 2026-06-30 [sec].
- Shareholders' equity of $353.7M as of 2026-06-30 [sec].
- Dabogratinib (TYRA-300) achieved a 57% complete response rate in the Phase 2 SURF302 trial for FGFR3-altered low-grade intermediate-risk NMIBC as of August 31, 2026 cutoff [news · 2026-09-16].
- First child dosed in BEACH301 Phase 2 study of dabogratinib for achondroplasia in August 2025, with initial results expected in the second half of 2026 [news · 2025-08-22].
What works
- Dabogratinib demonstrated clinical proof of concept with a 57% complete response rate in Phase 2 SURF302 for IR NMIBC, supporting potential as the first oral innovation in this indication [news · 2026-09-16].
- The company has a robust pipeline with multiple Phase 2 candidates (TYRA-300, TYRA-200, TYRA-430) targeting FGFR-driven cancers and achondroplasia [pipeline].
- Cash position of $73.8M as of 2026-06-30 provides a runway for ongoing clinical programs [sec].
What to weigh
- Net loss of -$45.6M as of 2026-06-30 reflects ongoing high R&D spending without approved product revenue [sec].
- Dabogratinib faces 16 competitors in the achondroplasia space, including BioMarin's vosoritide in Phase 2 and Phase 3 [pipeline].
- The company is heavily reliant on the success of dabogratinib, with multiple programs in early stages and no approved drugs [pipeline].
From the filings
Quoted directly from source documents.
Dabogratinib achieved 57% complete response rate in Phase 2 SURF302
“Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial.”
News · September 16, 2026
First child dosed in BEACH301 Phase 2 for achondroplasia
“On August 21, 2025, Tyra Biosciences, Inc. (Tyra or the Company) announced the first child has been dosed in the BEACH301 Phase 2 clinical study of dabogratinib (formerly TYRA-300) in children with achondroplasia.”
News · August 22, 2025
Risks & what to watch (3)›
Key risks
- High net loss — Net loss of $45.6M as of 2026-06-30 indicates significant cash burn without revenue [sec].
- Competitive achondroplasia landscape — 16 competitors in achondroplasia, including BioMarin's vosoritide in Phase 2/3 [pipeline].
- Dependence on dabogratinib — Pipeline heavily relies on dabogratinib; other candidates are early-stage [pipeline].
What to watch
- Initial results from the BEACH301 Phase 2 safety sentinel cohort for dabogratinib in achondroplasia expected in the second half of 2026 [news · 2025-08-22].
- Further data from SURF302 Phase 2 for dabogratinib in IR NMIBC and potential Phase 3 planning [news · 2026-09-16].
- Progress of TYRA-200 and TYRA-430 in Phase 2 for metastatic hepatocellular carcinoma [pipeline].
Sources: Catalysts · News · Pipeline · Generated October 13, 2026 · How we verify sources →
Run Tyra Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tyra Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.08 · 0% dilution
Lead: Phase 2
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of Apr 19, 2026- % of float
- 22.4%
- Days to cover
- 6.2
- Shares short
- 8,264,887
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TYRA short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tyra Biosciences, Inc.?
Tyra Biosciences (TYRA) is a clinical-stage biotechnology company developing next-generation precision FGFR inhibitors, with a lead candidate dabogratinib showing a 57% complete response rate in a Phase 2 trial for intermediate-risk non-muscle invasive bladder cancer as of September 2026.
What is Tyra Biosciences, Inc.'s lead drug candidate?
Tyra Biosciences, Inc.'s most advanced tracked candidate is dabogratinib (Phase 2) for Low Grade Upper Tract Urothelial Carcinoma.
Who is the CEO of Tyra Biosciences, Inc.?
Dr. Todd Harris Ph.D. is the chief executive officer of Tyra Biosciences, Inc. (TYRA).
Where is Tyra Biosciences, Inc. headquartered?
Tyra Biosciences, Inc. (TYRA) is headquartered in Carlsbad, CA, United States.
What therapeutic areas does Tyra Biosciences, Inc. focus on?
Tyra Biosciences, Inc. develops therapies across Oncology, Rare Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.